论文部分内容阅读
背景与目的:由于肿瘤存在异质性,患同种肿瘤的不同患者对化疗药物具有不同对敏感性,研究显示,近年发展起来的ATP肿瘤体外药敏试验(ATP-TCA)对肿瘤患者对个体化治疗具有较大的指导价值。本研究探讨ATP-肿瘤体外药敏试验(ATP-TCA)应用于卵巢癌化疗的可行性,比较PEOC手术标本对5种化疗药物的体外敏感性。方法:采用ATP-TCA法对24例原发上皮性卵巢癌患者手术切除的新鲜癌组织进行体外药物敏感性测定,分别检测对紫杉醇(泰素)、顺铂、吉西他滨(健择)、多柔比星(阿霉素)、拓扑替康5种化疗药物的敏感性。结果:24例上皮性卵巢癌手术标本中,ATP-TCA可评价率95.83%,所测标本对药物的体外敏感率依次为泰素91.30%,吉西他滨86.96%、多柔比星65.22%、拓扑替康47.83%、顺铂21.74%。按ATP-TCA药敏结果进行个体化化疗,近期疗效较好,肿瘤缓解率高。结论:ATP-TCA是一种简便、敏感、标准化的方法,在卵巢癌临床化疗筛选用药方面值得进一步研究。
BACKGROUND & OBJECTIVE: Due to the heterogeneity of tumors, different patients with the same type of tumor have different sensitivity to chemotherapeutic drugs. Studies have shown that ATP-TCA, developed in recent years, The treatment has a greater guiding value. This study was to investigate the feasibility of ATP-TCA in ovarian cancer chemotherapy and to compare the sensitivity of PEOC in vitro to five chemotherapeutic drugs. Methods: 24 cases of primary epithelial ovarian cancer were excised by ATP-TCA method in vitro. The drug susceptibility was measured in vitro. The effects of paclitaxel (paclitaxel), cisplatin, gemcitabine Bismuth (doxorubicin), Topotecan 5 chemotherapy chemosensitivity. Results: In 24 specimens of epithelial ovarian cancer, the evaluation rate of ATP-TCA was 95.83%. The in vitro sensitivity of the tested specimens was 91.30% of taxol, 86.96% of gemcitabine, 65.22% of doxorubicin, Kang 47.83%, cisplatin 21.74%. According to ATP-TCA susceptibility results for individualized chemotherapy, the recent curative effect is better, the tumor remission rate is high. Conclusion: ATP-TCA is a simple, sensitive and standardized method that is worth further study in clinical chemotherapy and drug selection for ovarian cancer.